In analogy to findings in first diagnosed DLBCL [35], alteration of p53 expression, which is a known marker for high clinical stage [36] but not for adverse survival [37], was not associated with BMI subgroups in the present cohort. Here, TP53 is linked to diffuse large B-cell lymphoma.